Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1569

Similar articles for PubMed (Select 19047115)

1.

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT.

Clin Cancer Res. 2008 Dec 1;14(23):7861-70. doi: 10.1158/1078-0432.CCR-08-1056.

2.

[Human epidermal growth factor receptor 2 expression in rectal cancer and its clinical implication].

Wang X, Sun Y, Gao J, Zheng J, Shen L.

Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Jun 25;18(6):597-601. Chinese.

PMID:
26108777
3.

Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.

Sardesai SD, Storniolo AM.

Womens Health (Lond Engl). 2015 Jun;11(3):281-94. doi: 10.2217/whe.15.9.

PMID:
26102468
4.

[Doubling time of progression-free survival by palbociclib in metastatic breast cancer].

L'Allemain G.

Bull Cancer. 2015 Apr;102(4):300. doi: 10.1016/j.bulcan.2015.02.011. French. No abstract available.

PMID:
26042255
5.

MET in gastric cancer - discarding a 10% cutoff rule.

Metzger ML, Behrens HM, Böger C, Haag J, Krüger S, Röcken C.

Histopathology. 2015 May 28. doi: 10.1111/his.12745. [Epub ahead of print]

PMID:
26033401
6.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.

Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G.

J Transl Med. 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0.

7.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 May 27. [Epub ahead of print]

PMID:
26020126
8.
9.

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2015 Apr 30;5:30. doi: 10.1186/s13550-015-0103-5. eCollection 2015.

10.

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma.

Jiang D, Li X, Wang H, Shi Y, Xu C, Lu S, Huang J, Xu Y, Zeng H, Su J, Hou Y, Tan L.

BMC Cancer. 2015 May 8;15:377. doi: 10.1186/s12885-015-1393-8.

11.

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, Boczek U, Stanek K, Kitz J, Wolff HA, Ghadimi BM, Middel P, Liersch T, Rüschoff J, Conradi LC.

Oncotarget. 2015 Apr 13. [Epub ahead of print]

12.

Quantification of HER family receptors in breast cancer.

Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M.

Breast Cancer Res. 2015 Apr 9;17:53. doi: 10.1186/s13058-015-0561-8.

13.

The utility of MYC and FLT4 in the diagnosis and treatment of postradiation atypical vascular lesion and angiosarcoma of the breast.

Cornejo KM, Deng A, Wu H, Cosar EF, Khan A, St Cyr M, Tomaszewicz K, Dresser K, O'Donnell P, Hutchinson L.

Hum Pathol. 2015 Jun;46(6):868-75. doi: 10.1016/j.humpath.2015.02.014. Epub 2015 Mar 10.

PMID:
25864386
14.

Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.

Lin NU.

J Clin Oncol. 2015 May 10;33(14):1530-3. doi: 10.1200/JCO.2014.60.1427. Epub 2015 Apr 6. No abstract available.

PMID:
25847924
15.

Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.

Qiao JH, Jiao C, Lu ZD, Yang S, Liu ZZ.

Tumour Biol. 2015 Apr 7. [Epub ahead of print]

PMID:
25846735
16.

HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein array.

Perry C, Conway CM, Ha JW, Braunschweig T, Morris J, Ylaya K, Cho H, Chung JY, Hewitt SM.

Clin Proteomics. 2014 Oct 1;11(1):36. doi: 10.1186/1559-0275-11-36. eCollection 2014.

17.

The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.

Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T, Naghshvar F.

J Cancer Res Clin Oncol. 2015 Mar 29. [Epub ahead of print]

PMID:
25820598
18.

National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.

Rakha EA, Pigera M, Shaaban A, Shin SJ, D'Alfonso T, Ellis IO, Lee AH.

J Clin Oncol. 2015 Apr 10;33(11):1301-2. doi: 10.1200/JCO.2014.59.7211. Epub 2015 Mar 9. No abstract available.

PMID:
25753440
19.

Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.

Chen H, Ye Q, Lv J, Ye P, Sun Y, Fan S, Su X, Gavine P, Yin X.

Pathol Oncol Res. 2015 Mar 9. [Epub ahead of print]

PMID:
25749810
20.

Metastatic, her-2 amplified lacrimal gland carcinoma with response to lapatinib treatment.

Dennie T.

Case Rep Oncol Med. 2015;2015:262357. doi: 10.1155/2015/262357. Epub 2015 Feb 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk